Unified Calculator View

All 9 guideline modules in a single page. Enter patient data across modules and view aggregated results below. Data is shared automatically between modules via the PREVENT risk calculator.

Modules1Risk Calculator 2Primary Prevention 3Secondary Prevention 4Severe Hyperchol.5Hypertriglyceridemia 6Diabetes 7Special Populations 8Lp(a) & ApoB 9Monitoring

0 of 9 modules completed

PREVENT-ASCVD Risk Calculator

Enter patient parameters to calculate 10-year and 30-year ASCVD risk

Demographics

Age*

years

30-79 years

Sex*

Lipid Panel

Total Cholesterol*

mg/dL

HDL Cholesterol*

mg/dL

Additional Labs(optional)

LDL Cholesterol

mg/dL

Optional -- used for treatment decisions, not risk calculation

Triglycerides

mg/dL

Optional

Fasting Lipid Panel?

Vitals & Labs

Systolic Blood Pressure*

mmHg

Diastolic Blood Pressure

mmHg

eGFR*

mL/min

Clinical History

On Antihypertensive?

On Statin?

Diabetes?

Current Smoker?

Months Since Quitting Smoking

months

These fields are optional and pre-populate other calculator modules

Results

Fill in required fields to see risk results

Complete Risk Assessment First

Please complete the PREVENT Risk Calculator (Module 1) to generate a risk score before proceeding with primary prevention recommendations.

Go to Risk Calculator

Secondary Prevention: ASCVD Risk Assessment

For patients WITH established atherosclerotic cardiovascular disease. Complete the form below to determine risk stratification and guideline-directed therapy.

ASCVD Event History

Select all prior major ASCVD events

Prior myocardial infarction (MI)?

Prior ischemic stroke?

Symptomatic PAD?

Multiple ASCVD events?

Current Lipid-Lowering Therapy

Enter current LDL-C level and medications

Current LDL-C*

mg/dL

Current statin intensity

On ezetimibe?

On PCSK9 inhibitor?

Statin intolerant?

Additional High-Risk Conditions

Check all conditions that apply. These influence risk stratification (high vs very high).

Age >= 65 yearsHeterozygous familial hypercholesterolemia (FH)Diabetes mellitusHypertension (on antihypertensive therapy)Chronic kidney disease (eGFR < 60 mL/min/1.73 m²)Current smokingPrior CABG or PCI (coronary revascularization)History of heart failure

Hypertriglyceridemia Assessment

Enter patient data to classify triglyceride level and generate a management plan.

Triglyceride Level*

mg/dL

Fasting level preferred

Age*

years

ASCVD History*

Currently on Statin*

Diabetes*

Diabetes-Specific Lipid Assessment

Enter patient data for diabetes-specific risk stratification and lipid management recommendations.

Age*

years

Diabetes Type*

Current LDL-C*

mg/dL

Current Statin Status*

eGFR*

mL/min/1.73m\u00B2

Diabetes Duration

years

Established ASCVD*

Risk-Enhancing Factors

Select all that apply (Source: Table 17 diabetes-specific + Table 13 general)

Special Population Guidance

Select a population for guideline-specific statin and lipid management recommendations

CKD Assessment

eGFR

mL/min

Enter eGFR to see stage-specific guidance

Statin Guidance

Class I / Level C-EO

Follow standard statin recommendations. CKD is a recognized risk-enhancing factor.

Recommendation

CKD Stage 1-2 (eGFR ≥60): Manage lipids per standard primary or secondary prevention pathways. CKD at this stage is a risk-enhancing factor that favors statin initiation. No CKD-specific recommendation exists for stages 1-2.

Source: Clinical practice — no CKD-specific recommendation for stages 1-2; manage per standard pathways

Understanding the Evidence Rating

Drug Interactions & Contraindications

Drug Interactions

Avoid simvastatin >20 mg with cyclosporine

Preferred statins in CKD: atorvastatin, rosuvastatin, pitavastatin (renal-safe profiles)

Clinical Pearls

CKD is a recognized risk-enhancing factor at any stage.
Statins do not adversely affect kidney function and may slow CKD progression.
PCSK9 mAbs have not been studied in those with GFR <20 mL/min/1.73 m²; use with caution at very low eGFR.
Rosuvastatin should be capped at 10 mg for eGFR <30.
CKD + ASCVD: high-intensity statin, target LDL-C <55 mg/dL, non-HDL-C <85 mg/dL (Rec 2, COR 1, LOE B-R).

Patient Context

Provide risk context for goal-directed interpretation

ASCVD Risk Category

LDL-C

mg/dL

Patient has established ASCVD

Lipoprotein(a) Assessment

Lp(a) is a genetically determined, independent risk factor for ASCVD

Lp(a)

nmol/L

Table 4 tiers: <75 Reference, 75-124 Borderline, 125-249 Elevated, 250+ High/Very High/Extreme

Apolipoprotein B Assessment

ApoB reflects atherogenic particle number and is a secondary treatment target

ApoB

mg/dL

Total Cholesterol

mg/dL

HDL-C

mg/dL

Should You Measure Lp(a) and ApoB?

Guideline indications for when to obtain these measurements

Lp(a) Measurement

COR 1, LOE B-NR

Lp(a) measurement is recommended at least once in all adults for ASCVD risk assessment (COR 1, LOE B-NR). This is a universal recommendation — no special indication is required.

Assay Guidance

Use laboratories employing assays that are insensitive to apolipoprotein(a) [apo(a)] isoforms and traceable to official reference standard materials to more accurately measure Lp(a) and characterize ASCVD risk (COR 1, LOE B-NR). Molar units (nmol/L) are preferred over mass units (mg/dL) due to variability in apo(a) isoform size. Source: Section 3.4, Recommendation 3.

ApoB Measurement

COR IIb, LOE B-NR

No specific indication identified based on the current patient context. ApoB is most useful when triglycerides are 150-499 mg/dL, or in patients with diabetes or CKM syndrome.

Monitoring & Follow-Up

Generate a personalized monitoring schedule and goal assessment

Statin Intensity

eGFR

mL/min

Current LDL-C

mg/dL

LDL-C Goal

mg/dL

New statin initiation (or recent dose change)Established ASCVD (secondary prevention)Statin intolerant

Current Therapies (for goal assessment)

EzetimibeBempedoic acidPCSK9 inhibitorInclisiran

Monitoring Schedule

Guideline-based monitoring recommendations (COR I, LOE B-NR)

Test	Timing	Rationale
Lipid Monitoring
Lipid panel (nonfasting acceptable in most patients; fasting if known hypertriglyceridemia)	4-12 weeks after initiation or dose change	Assess LDL-C response to therapy. Expect ≥30% reduction with moderate-intensity, ≥50% with high-intensity statin.
Lipid panel (nonfasting acceptable in most patients; fasting if known hypertriglyceridemia)	Every 6-12 months once stable	Monitor adherence and sustained LDL-C response. Annual minimum.
Lipoprotein(a) [Lp(a)]	Once in adult lifetime (at initial lipid assessment)	Lp(a) is genetically determined and stable over a lifetime. ≥125 nmol/L is risk-enhancing. Measure at least once (COR 1, LOE B-NR).
Safety Labs
Hepatic function panel (ALT)	Baseline prior to statin initiation	Baseline hepatic function. Routine monitoring no longer required unless symptoms develop.
Follow-Up
Clinical follow-up visit	4-12 weeks after initiation, then every 6-12 months	Assess adherence, tolerability, lifestyle modification progress, and treatment goals.

Aggregated Results

Complete modules above to see aggregated results.

This tool is intended for use by healthcare professionals and does not replace clinical judgment. Always refer to the full 2026 ACC/AHA Guideline on the Management of Dyslipidemia for complete recommendations.

All computation occurs entirely in your browser. No patient data is transmitted, stored, or logged.

Unified Calculator View

PREVENT-ASCVD Risk Calculator

Demographics

Lipid Panel

Vitals & Labs

Clinical History

Results

Secondary Prevention: ASCVD Risk Assessment

ASCVD Event History

Current Lipid-Lowering Therapy

Additional High-Risk Conditions

LDL-C Severity Assessment

Dutch Lipid Clinic Network (DLCN) Score

1. Family History

2. Personal Clinical History

3. Physical Examination

4. LDL-C Level (Untreated)

5. DNA Analysis

Classification

Lipoprotein(a) Assessment

Why measure Lp(a) in this patient?

Hypertriglyceridemia Assessment

Diabetes-Specific Lipid Assessment

Risk-Enhancing Factors

Special Population Guidance

CKD Assessment

Statin Guidance

Drug Interactions & Contraindications

Drug Interactions

Clinical Pearls

Patient Context

Lipoprotein(a) Assessment

Apolipoprotein B Assessment

Should You Measure Lp(a) and ApoB?

Lp(a) Measurement

ApoB Measurement

Monitoring & Follow-Up

Monitoring Schedule

PREVENT-ASCVD Risk Calculator

Demographics

Lipid Panel

Vitals & Labs

Clinical History

Results

Secondary Prevention: ASCVD Risk Assessment

ASCVD Event History

Current Lipid-Lowering Therapy

Additional High-Risk Conditions

LDL-C Severity Assessment

Dutch Lipid Clinic Network (DLCN) Score

1. Family History

2. Personal Clinical History

3. Physical Examination

4. LDL-C Level (Untreated)

5. DNA Analysis

Classification

Lipoprotein(a) Assessment

Why measure Lp(a) in this patient?

Hypertriglyceridemia Assessment

Diabetes-Specific Lipid Assessment

Risk-Enhancing Factors

Special Population Guidance

CKD Assessment

Statin Guidance

Drug Interactions & Contraindications

Drug Interactions

Clinical Pearls

Patient Context

Lipoprotein(a) Assessment

Apolipoprotein B Assessment

Should You Measure Lp(a) and ApoB?

Lp(a) Measurement

ApoB Measurement

Monitoring & Follow-Up

Monitoring Schedule